Patients with MS treated with Fingolimod or IFN-β have a significantly lower annualized relapse rate (ARR) (15, 16), so our analysis is reliable using the currently reported transcriptomic dataset of MS patients treated with these two drugs. Here, IFNB1 is linked to myeloid sarcoma.